Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050268 | 0.88 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3HRH3CCR2 | |
| SCHEMBL31050339 | 0.88 | SLC6A4 (0.35) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20563260 | 0.87 | TAAR1 (0.43) | SLC6A4SLC6A2SLC6A3TAAR1SMN1; SMN2 | |
| SCHEMBL31503518 | 0.85 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| SCHEMBL16952861 | 0.83 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1016506 | 0.82 | CYP2A6 (0.40) | SLC6A4SLC6A2SLC6A3HRH3SMN1; SMN2 | |
| SCHEMBL7820988 | 0.79 | SLC6A4 (0.34) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| SCHEMBL3107273 | 0.77 | ALDH1A1 (0.38) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| SCHEMBL31488655 | 0.75 | SLC6A4 (0.32) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL2645981 | 0.75 | ALOX15 (0.42) | ALDH1A1CCR2MAPK1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283660-B2 | Small molecule semiconductor | XEROX CORPORATION (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120161109-A1 | SMALL MOLECULE SEMICONDUCTOR | XEROX CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120161109-A1 | SMALL MOLECULE SEMICONDUCTOR | SLC43A1, TST, SLC7A5 | SLC6A4 221/4885SLC6A2 239/4885SLC6A3 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.